Valneva SE Sponsored ADR (NASDAQ:VALN) Sees Large Increase in Short Interest

Key Points

• Short interest in Valneva SE rose significantly by 91.2%, totaling 45,500 shares as of July 31, compared to 23,800 shares on July 15, indicating increased bearish sentiment among investors.
• Valneva reported earnings of ($0.16) per share, surpassing analysts' estimates of ($0.27) and achieving revenue of $54.84 million for the quarter, exceeding expectations of $46.28 million.
• Institutional investors have recently increased their positions in Valneva, with GAMMA Investing LLC and Frazier Life Sciences Management L.P. recently making significant purchases.

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 45,500 shares, agrowthof91.2% from the July 15th total of 23,800 shares. Based on an average trading volume of 52,800 shares, the days-to-cover ratio is presently 0.9 days. Currently,0.1% of the company's stock are sold short. Currently,0.1% of the company's stock are sold short. Based on an average trading volume of 52,800 shares, the days-to-cover ratio is presently 0.9 days.

Hedge Funds Weigh In On Valneva

Several large investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. bought a new stake in Valneva during the 2nd quarter valued at approximately $8,240,000. Wells Fargo & Company MN grew its position in Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after acquiring an additional 30,859 shares during the period. GAMMA Investing LLC acquired a new stake in shares of Valneva in the 1st quarter valued at $94,000. Finally, Marex Group plc bought a new stake in shares of Valneva in the 2nd quarter worth about $64,000. Institutional investors and hedge funds own 11.39% of the company's stock.

Valneva Stock Performance

VALN traded down $0.29 on Thursday, hitting $11.21. The company had a trading volume of 52,374 shares, compared to its average volume of 63,563. The stock has a market cap of $953.86 million, a price-to-earnings ratio of -11.46 and a beta of 1.77. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77. The company's fifty day moving average price is $7.20 and its 200 day moving average price is $6.88. Valneva has a 1-year low of $3.62 and a 1-year high of $12.25.

Valneva (NASDAQ:VALN - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. The business had revenue of $54.84 million for the quarter, compared to analyst estimates of $46.28 million. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. Equities analysts predict that Valneva will post 0.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

VALN has been the topic of several research reports. HC Wainwright assumed coverage on shares of Valneva in a research note on Tuesday. They issued a "buy" rating and a $18.00 price objective on the stock. Guggenheim cut their price objective on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Valneva has a consensus rating of "Buy" and a consensus price target of $16.00.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.